Related Experiment Video

Updated: Feb 15, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.2K

[Hepatitis C-related hepatocellular carcinoma and the treatment with direct-acting antiviral agents]

X Liu1, Y H Gao, J Q Niu

  • 1Department of Hepatology, First Hospital of Jilin University, Changchun 130021, China.

Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chinese Journal of Hepatology
|January 12, 2018
PubMed

Insights

Direct-acting antiviral agents (DAAs) effectively treat chronic hepatitis C. This review examines DAA use in patients with hepatitis C virus-related liver cancer, addressing safety and efficacy concerns.

Area of Science:

  • Hepatology
  • Virology
  • Oncology

Background:

  • Direct-acting antiviral agents (DAAs) have revolutionized chronic hepatitis C treatment, leading to high sustained virological response rates.
  • Hepatocellular carcinoma (HCC) remains a significant concern in patients with chronic hepatitis C.
  • The role and safety of DAAs in the context of HCC are not yet fully established, necessitating further investigation.

Purpose of the Study:

  • To evaluate the current evidence on the use of DAAs in patients with hepatitis C virus-related HCC.
  • To determine if DAA therapy impacts the incidence or recurrence rates of HCC.
  • To assess the efficacy and safety of DAAs in HCC patients undergoing or post-antitumor treatment.

Main Methods:

  • Systematic review and critical evaluation of existing literature.
  • Analysis of studies investigating DAA treatment in hepatitis C patients with and without HCC.
  • Examination of data on HCC incidence, recurrence, and treatment outcomes in patients receiving DAAs.

Main Results:

  • Evidence regarding DAA impact on HCC incidence/recurrence is conflicting and requires further research.
  • DAAs show potential efficacy in treating hepatitis C in HCC patients after antitumor therapy.
  • Safety profiles of DAAs in this specific patient population need continued monitoring.

Conclusions:

  • The application of DAAs in hepatitis C virus-related HCC management requires careful consideration.
  • Further prospective studies are essential to clarify the risks and benefits of DAAs in HCC patients.
  • Personalized treatment strategies are crucial for optimizing outcomes in this complex patient group.
Keywords:
Carcinoma, hepatocellularDirect antiviral drugsHepatitis C, chronicTherapy

More Related Videos

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice10:35

Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice

Published on: September 25, 2013

37.2K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Concept Videos

Adrenergic Agonists: Direct-Acting Agents01:30

Adrenergic Agonists: Direct-Acting Agents

Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
2.9K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.9K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.8K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.7K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.4K